Xydalba: Uses, Dosage & Side Effects
A long-acting glycopeptide antibiotic for the treatment of acute bacterial skin and skin structure infections (ABSSSI) in adults and children
Xydalba (dalbavancin) is a long-acting lipoglycopeptide antibiotic used to treat acute bacterial skin and skin structure infections (ABSSSI) in adults and children from birth. It belongs to the glycopeptide class of antibiotics, related to vancomycin and teicoplanin, and works by disrupting bacterial cell wall synthesis in susceptible Gram-positive organisms, including methicillin-resistant Staphylococcus aureus (MRSA). What makes Xydalba unique among antibiotics is its remarkably long half-life of approximately 14 days, which allows the entire treatment course to be completed with either a single intravenous infusion or two doses given one week apart. This eliminates the need for prolonged daily intravenous antibiotic therapy and can significantly reduce hospital stays.
Quick Facts: Xydalba
Key Takeaways
- Xydalba (dalbavancin) is a glycopeptide antibiotic with an exceptionally long half-life (~14 days), enabling the full treatment of acute bacterial skin infections with just one or two intravenous doses instead of daily antibiotic therapy.
- It is effective against a broad range of Gram-positive bacteria including MRSA, making it a valuable option for serious skin infections such as cellulitis, wound infections, and major cutaneous abscesses.
- The most common side effects are mild and include headache, nausea, and diarrhea; serious allergic reactions and Clostridioides difficile-associated diarrhea are rare but require immediate medical attention.
- Adults can receive Xydalba as a single 1,500 mg dose or as two doses (1,000 mg on day 1 and 500 mg on day 8); pediatric dosing is weight-based and varies by age group.
- Xydalba is not recommended during pregnancy or breastfeeding unless clearly necessary; patients with kidney problems may require dose adjustments.
What Is Xydalba and What Is It Used For?
Xydalba contains the active substance dalbavancin, a semisynthetic lipoglycopeptide antibiotic. Lipoglycopeptides are an advanced subclass of glycopeptide antibiotics that have been structurally modified with a lipophilic (fat-soluble) side chain. This modification gives dalbavancin enhanced properties compared to older glycopeptides: improved binding to its bacterial target, greater potency against many Gram-positive pathogens, and a dramatically extended elimination half-life that enables infrequent dosing. Dalbavancin was originally derived from the naturally occurring glycopeptide A-40926, produced by the actinomycete Nonomuraea species.
The mechanism of action of dalbavancin involves binding to the D-alanyl-D-alanine terminal residues of the lipid II peptidoglycan precursor molecule on the surface of bacterial cells. Peptidoglycan is an essential structural component of bacterial cell walls, and its synthesis requires the cross-linking of precursor molecules by transpeptidase and transglycosylase enzymes. By binding tightly to the D-Ala-D-Ala terminus of lipid II, dalbavancin physically blocks both the transglycosylation and transpeptidation steps of peptidoglycan synthesis. Without a properly formed cell wall, the bacterial cell cannot maintain its structural integrity, leading to osmotic instability, cell lysis, and ultimately bacterial death. This bactericidal mechanism is concentration-dependent and time-dependent, with the prolonged tissue exposure afforded by dalbavancin's long half-life contributing to sustained bacterial killing.
Xydalba is indicated for the treatment of acute bacterial skin and skin structure infections (ABSSSI) in adults and children from birth onwards. ABSSSI is a category of infections that encompasses a wide range of clinical presentations, including:
- Cellulitis and erysipelas: Spreading infections of the skin and subcutaneous tissue, characterized by redness, warmth, swelling, and pain. These infections can range from mild to severe and may be accompanied by systemic symptoms such as fever and malaise.
- Wound infections: Infections that develop in surgical or traumatic wounds. These may involve erythema, purulent drainage, and tissue destruction extending beyond the wound margins.
- Major cutaneous abscesses: Localized collections of pus within the dermis and deeper skin tissues, typically caused by Staphylococcus aureus. Major abscesses are those with a minimum lesion surface area of approximately 75 cm² and are accompanied by surrounding cellulitis.
The Gram-positive bacteria most commonly responsible for ABSSSI include Staphylococcus aureus (both methicillin-susceptible and methicillin-resistant strains), Streptococcus pyogenes (Group A streptococcus), Streptococcus agalactiae (Group B streptococcus), Streptococcus anginosus group, and Enterococcus faecalis (vancomycin-susceptible strains only). Dalbavancin has demonstrated potent in vitro activity against all of these organisms. Importantly, it retains full activity against MRSA, which is a leading cause of skin infections worldwide and is resistant to many first-line antibiotics.
It is important to understand that Xydalba is not effective against infections caused by Gram-negative bacteria. Gram-negative organisms have an outer membrane that prevents glycopeptide antibiotics from reaching their peptidoglycan targets. If your doctor suspects that your infection may also involve Gram-negative bacteria, additional antibiotics may be prescribed alongside Xydalba to ensure comprehensive coverage.
The most distinctive feature of Xydalba is its exceptionally long terminal elimination half-life of approximately 14.4 days (346 hours). This is far longer than any other approved antibiotic. For comparison, vancomycin has a half-life of 4–6 hours and teicoplanin approximately 150 hours. This pharmacokinetic property means that a single intravenous dose of dalbavancin maintains effective antibiotic concentrations in the body for approximately two weeks, allowing complete treatment of ABSSSI without the need for daily antibiotic administration, outpatient parenteral therapy, or prolonged hospitalization.
The clinical efficacy of Xydalba in treating ABSSSI has been established through robust phase III clinical trials. The DISCOVER 1 and DISCOVER 2 trials were large, randomized, double-blind, multinational studies that compared dalbavancin (given as two doses: 1,000 mg on day 1 and 500 mg on day 8) with vancomycin followed by oral linezolid. Both trials demonstrated that dalbavancin was non-inferior to the comparator regimen across all primary and key secondary endpoints. A subsequent trial evaluated the single-dose 1,500 mg regimen and confirmed its non-inferiority to the two-dose regimen, further simplifying the treatment approach.
What Should You Know Before Taking Xydalba?
Contraindications
The primary contraindication for Xydalba is a known hypersensitivity (allergy) to dalbavancin or to any of the other ingredients contained in the formulation. The inactive ingredients include mannitol (E421), lactose monohydrate, hydrochloric acid, and sodium hydroxide (used for pH adjustment). If you have previously experienced an allergic reaction to dalbavancin, you must not receive Xydalba under any circumstances.
While not an absolute contraindication, patients with a known allergy to other glycopeptide antibiotics, such as vancomycin or teicoplanin, should exercise particular caution. Cross-sensitivity between glycopeptides has been reported, and your doctor will carefully assess the risk-benefit ratio before proceeding with treatment. If you have ever had a severe allergic reaction to vancomycin or teicoplanin, inform your healthcare provider before receiving Xydalba.
Warnings and Precautions
Seek immediate medical attention if you experience sudden swelling of the lips, face, throat, or tongue; severe rash; itching; throat tightness; a drop in blood pressure; difficulty swallowing; or difficulty breathing after receiving Xydalba. These may be signs of a hypersensitivity reaction (anaphylaxis) that can be life-threatening. This reaction has been reported as a rare side effect.
Talk to your doctor, pharmacist, or nurse before you receive Xydalba if any of the following apply to you:
- Kidney problems: If you have or have had kidney problems, your doctor may need to reduce your dose. Depending on your age and the condition of your kidneys, dose adjustment may be required. There is insufficient data to recommend Xydalba in children with chronic kidney disease.
- History of antibiotic-associated diarrhea: If you have previously experienced diarrhea during or after antibiotic treatment, you may be at increased risk for Clostridioides difficile-associated diarrhea (CDAD). This potentially serious bowel infection can occur during or after treatment with almost any antibiotic, including Xydalba.
- Allergy to glycopeptides: If you are allergic to other glycopeptide antibiotics such as vancomycin or teicoplanin, there may be a risk of cross-reactivity with dalbavancin.
If you develop diarrhea during or after treatment with Xydalba, contact your doctor immediately. Do not take any medicines to treat diarrhea without first consulting your doctor. Diarrhea may be a sign of a bowel infection caused by Clostridioides difficile, which can range from mild to life-threatening. Antidiarrheal medications that slow bowel movements could worsen this condition.
As with all antibiotics, treatment with Xydalba may occasionally allow the overgrowth of organisms that are not susceptible to the drug, including fungi. Superinfection with non-susceptible organisms, such as oral thrush (candidiasis) or vaginal yeast infections, may develop during or after treatment. If you notice signs of a new infection, tell your doctor so that appropriate treatment can be initiated.
Infusion-Related Reactions
Intravenous infusion of glycopeptide-type antibiotics, including dalbavancin, can cause flushing of the upper body, hives (urticaria), itching (pruritus), and skin rash. These reactions are sometimes referred to as “red man syndrome” and are related to the rate of infusion rather than a true allergy. If you experience any of these symptoms during the infusion, your doctor may decide to stop the infusion temporarily or slow the infusion rate. These infusion-related reactions are generally manageable and do not necessarily prevent future use of the medication.
Pregnancy and Breastfeeding
Xydalba is not recommended during pregnancy unless the potential clinical benefit clearly outweighs the possible risk to the unborn baby. The effects of dalbavancin on human pregnancy have not been adequately studied, and it is not known whether the drug can cause harm to the developing fetus. Animal reproductive toxicity studies have provided limited data. If you are pregnant, think you may be pregnant, or are planning to become pregnant, discuss this with your doctor before receiving Xydalba. You and your doctor will decide together whether treatment is appropriate in your situation.
It is not known whether dalbavancin is excreted in human breast milk. Because many drugs are excreted in breast milk and because of the potential for adverse effects in breastfed infants, you should not breastfeed while receiving Xydalba. Discuss with your doctor the best approach to feeding your infant during and after treatment.
Driving and Operating Machinery
Xydalba may cause dizziness in some patients. If you experience dizziness after receiving this medicine, exercise caution when driving or operating machinery until you know how the drug affects you. Do not drive or operate heavy machinery if you feel dizzy or unwell.
Sodium Content
This medicine contains less than 1 mmol (23 mg) of sodium per dose, which means it is essentially sodium-free. This is relevant for patients who are on a controlled sodium diet, such as those with heart failure or kidney disease.
How Does Xydalba Interact with Other Drugs?
Drug interaction studies have shown that dalbavancin has a low propensity for pharmacokinetic drug-drug interactions. Dalbavancin is not significantly metabolized by cytochrome P450 (CYP) enzymes, nor does it inhibit or induce major CYP isoforms at clinically relevant concentrations. It is not a substrate, inhibitor, or inducer of P-glycoprotein or other major drug transporters. These characteristics give Xydalba a favorable drug interaction profile compared to many other antimicrobial agents.
Despite the favorable pharmacokinetic profile, certain pharmacodynamic interactions should be considered. Because dalbavancin, like all glycopeptides, has the potential for nephrotoxicity and ototoxicity, caution is warranted when co-administering it with other drugs that carry similar risks.
Potential Interactions
| Interacting Drug | Effect | Clinical Significance |
|---|---|---|
| Aminoglycosides (e.g., gentamicin, amikacin) | Additive nephrotoxicity and ototoxicity risk | Monitor kidney function and hearing if co-administered |
| Vancomycin | Additive nephrotoxicity; pharmacodynamic overlap | Avoid concurrent use; sequential use may be appropriate with monitoring |
| Warfarin | Potential alteration of INR due to antibiotic effects on gut flora | Monitor INR more frequently during and after treatment |
| Loop diuretics (e.g., furosemide) | Additive ototoxicity risk | Monitor hearing function; use cautiously |
| NSAIDs (e.g., ibuprofen, naproxen) | Possible additive nephrotoxicity in susceptible patients | Adequate hydration; monitor renal function in at-risk patients |
Always inform your doctor or pharmacist about all medications you are currently taking, have recently taken, or might take. This includes prescription medicines, over-the-counter drugs, herbal supplements, and vitamins. Although Xydalba has a favorable interaction profile, comprehensive medication review ensures the safest possible treatment.
In clinical studies, no dose adjustments were required when dalbavancin was co-administered with commonly used medications such as aztreonam, metronidazole, or proton pump inhibitors. However, the long duration of dalbavancin exposure (approximately two weeks after a single dose) means that any potential interaction could have a prolonged effect.
What Is the Correct Dosage of Xydalba?
Xydalba is always prepared and administered by a doctor or nurse as an intravenous infusion delivered over 30 minutes. You will not self-administer this medication. The powder must be reconstituted and diluted before use, and the infusion must be given directly into a vein.
Adults
Single-Dose Regimen
Dose: 1,500 mg administered as a single intravenous infusion over 30 minutes
Advantage: Completes the entire course of antibiotic treatment in a single hospital visit
This regimen is particularly beneficial for patients who may have difficulty returning for a second dose, or in settings where outpatient parenteral antibiotic therapy (OPAT) services are limited.
Two-Dose Regimen
Day 1: 1,000 mg administered as an intravenous infusion over 30 minutes
Day 8: 500 mg administered as an intravenous infusion over 30 minutes
This was the regimen used in the original pivotal clinical trials (DISCOVER 1 and DISCOVER 2) and has the longest track record of clinical evidence.
Children and Adolescents
Dosing for children is calculated by the doctor based on the child’s age and body weight. The dose should not exceed the maximum adult dose of 1,500 mg.
| Age Group | Dose | Maximum Dose | Administration |
|---|---|---|---|
| 6 years to <18 years | 18 mg/kg | 1,500 mg | Single IV infusion over 30 min |
| Birth to <6 years | 22.5 mg/kg | 1,500 mg | Single IV infusion over 30 min |
The higher weight-based dose for younger children (22.5 mg/kg versus 18 mg/kg for older children) reflects the faster drug clearance in younger pediatric patients due to developmental differences in drug metabolism and body composition. Your doctor will calculate the precise dose and volume to be administered based on your child’s exact weight.
Patients with Kidney Problems
If you have chronic kidney disease, your doctor may need to reduce your dose of Xydalba. Dalbavancin is partially eliminated through the kidneys, and impaired renal function can lead to higher drug levels in the body. Dose reduction is particularly important for patients with severe kidney impairment who are not receiving regular dialysis. There is currently insufficient data to recommend Xydalba for children with chronic kidney problems.
Missed Dose
If you are receiving the two-dose regimen and are concerned that you may have missed the second dose on day 8, contact your doctor or healthcare provider immediately. They will advise you on when to receive the second dose and whether any adjustments are needed. It is important not to delay the second dose unnecessarily, as this may reduce the effectiveness of treatment.
Overdose
If you are concerned that you may have received too much Xydalba, tell your doctor or nurse immediately. Because Xydalba is prepared and administered by healthcare professionals, overdose is unlikely. In clinical studies, no specific antidote has been identified for dalbavancin overdose, and treatment would be supportive. Dalbavancin is not efficiently removed by hemodialysis due to its high protein binding.
Xydalba is always prepared and administered by trained healthcare professionals. The powder must be reconstituted with sterile water for injection and then diluted with 5% glucose solution before infusion. Sodium chloride (normal saline) must NOT be used for reconstitution or dilution, as it can cause precipitation.
What Are the Side Effects of Xydalba?
Like all medicines, Xydalba can cause side effects, although not everybody gets them. Most side effects observed with dalbavancin have been mild to moderate in severity and are generally self-limiting. Your healthcare team will monitor you during and after the infusion and manage any side effects as needed.
Serious Side Effects
Contact your doctor immediately or seek emergency care if you experience any of the following: sudden swelling of the lips, face, throat, or tongue; severe rash or hives; itching; throat tightness; drop in blood pressure; difficulty swallowing or breathing. These may be signs of a serious allergic reaction (anaphylaxis). Also seek immediate attention for severe abdominal pain or persistent watery diarrhea, as these may indicate a Clostridioides difficile bowel infection. Do not take antidiarrheal medicines without consulting your doctor first.
Side Effects by Frequency
Common
May affect up to 1 in 10 people
- Headache
- Nausea
- Diarrhea
Uncommon
May affect up to 1 in 100 people
- Vaginal infections and yeast infections
- Oral thrush (candidiasis)
- Urinary tract infections
- Anemia (low red blood cell count)
- Thrombocytosis (elevated platelet count)
- Eosinophilia (elevated eosinophil white blood cells)
- Leukopenia and neutropenia (low white blood cell counts)
- Changes in other blood values
- Decreased appetite
- Difficulty sleeping (insomnia)
- Dizziness
- Taste disturbances (dysgeusia)
- Inflammation and swelling of superficial veins (phlebitis); flushing
- Cough
- Abdominal pain and discomfort; indigestion; constipation
- Abnormal liver function test results
- Elevated alkaline phosphatase levels
- Itching (pruritus); urticaria (hives)
- Genital itching (in women)
- Pain, redness, or swelling at the infusion site
- Feeling of warmth (flushing)
- Elevated gamma-glutamyltransferase (GGT)
- Rash
- Vomiting
- Clostridioides difficile bowel infection
Rare
May affect up to 1 in 1,000 people
- Anaphylaxis (severe, life-threatening allergic reaction)
- Bronchospasm (difficulty breathing due to airway narrowing)
Not Known
Frequency cannot be estimated from available data
- Hearing changes (reported with similar glycopeptide antibiotics)
Infusion-Related Reactions
As with other glycopeptide antibiotics, intravenous infusion of dalbavancin can cause infusion-related reactions. These may include flushing of the upper body, urticaria (hives), itching, and rash. These reactions are generally mild and related to the rate of infusion. If you experience any of these symptoms during the infusion, your doctor may temporarily stop the infusion or reduce the infusion rate. Pre-treatment with antihistamines may be considered in patients who have previously experienced infusion reactions.
Superinfections
As with all antibiotics, treatment with Xydalba may sometimes lead to new infections caused by organisms that are not susceptible to dalbavancin. This includes fungal infections such as vaginal candidiasis and oral thrush, as well as bacterial superinfections. If you develop signs of a new infection during or after treatment, inform your doctor so they can determine the appropriate course of action.
If you experience any side effects, including those not listed in this article, tell your doctor, pharmacist, or nurse. You can also report suspected side effects to your national pharmacovigilance authority (e.g., the EMA in Europe, the FDA MedWatch program in the United States, or the MHRA Yellow Card Scheme in the United Kingdom) to help monitor the ongoing safety of this medication.
How Should Xydalba Be Stored?
Keep this medicine out of the sight and reach of children. Do not use Xydalba after the expiry date stated on the vial label after “EXP.” The expiry date refers to the last day of that month.
- Unopened vials: No special storage conditions are required when stored in the original packaging. Store at room temperature.
- Reconstituted solution: After reconstitution with sterile water for injection, the concentrated solution (20 mg/mL) should be further diluted promptly.
- Diluted infusion solution: After dilution with 5% glucose solution, the infusion should be administered as soon as practicable.
- Single use only: Xydalba vials are intended for single use. Any unused reconstituted or diluted solution must be discarded.
- Visual inspection: Do not use if the solution contains particles or if it appears cloudy. The reconstituted solution should be a clear, colorless to pale yellow liquid.
As Xydalba is prepared and administered in a hospital or clinic setting, storage and handling will be managed by your healthcare team and hospital pharmacy. Unused medicine should not be disposed of via wastewater or household waste. Your healthcare facility will follow local regulations for proper disposal of pharmaceutical waste.
What Does Xydalba Contain?
Active Substance
The active substance is dalbavancin. Each single-use glass vial contains dalbavancin hydrochloride equivalent to 500 mg of dalbavancin. After reconstitution with 25 mL of sterile water for injection, the concentrated solution contains 20 mg/mL of dalbavancin.
Inactive Ingredients (Excipients)
- Mannitol (E421)
- Lactose monohydrate
- Hydrochloric acid (for pH adjustment)
- Sodium hydroxide (for pH adjustment)
Patients with rare hereditary problems of galactose intolerance, total lactase deficiency, or glucose-galactose malabsorption should be aware that Xydalba contains lactose monohydrate. Discuss this with your doctor if any of these conditions apply to you.
Appearance and Packaging
Xydalba is supplied as a white to off-white to pale yellow powder in a 48 mL glass vial with a green snap-off cap. It is available in packs of one vial. After reconstitution, the solution should be clear, colorless to pale yellow, and free of visible particles.
Manufacturer
Xydalba is marketed by AbbVie Deutschland GmbH & Co. KG, Ludwigshafen, Germany. Manufacturing is carried out by Almac Pharma Services (Ireland) Limited, Dundalk, Ireland; Almac Pharma Services Ltd, Craigavon, United Kingdom; and Aziende Chimiche Riunite Angelini Francesco A.C.R.A.F. S.p.A., Ancona, Italy. Xydalba is authorized for use in the European Union and other regulated markets worldwide.
Xydalba must be reconstituted with sterile water for injection and then diluted exclusively with 5% glucose (dextrose) solution. Sodium chloride solutions (normal saline) must NOT be used for reconstitution or dilution, as they can cause precipitation of the drug. If the same intravenous line is used for other medications, flush with 5% glucose solution before and after each Xydalba infusion. The final infusion concentration should be between 1 and 5 mg/mL.
Frequently Asked Questions About Xydalba
Xydalba (dalbavancin) is used to treat acute bacterial skin and skin structure infections (ABSSSI) in adults and children from birth. These infections include cellulitis, wound infections, and major cutaneous abscesses caused by susceptible Gram-positive bacteria, including methicillin-resistant Staphylococcus aureus (MRSA). It is given as an intravenous infusion in a hospital or clinic setting.
Xydalba has a uniquely long half-life of approximately 14 days, which is much longer than most antibiotics. This means that after a single intravenous infusion, therapeutic antibiotic concentrations are maintained in the body for about two weeks. This eliminates the need for daily antibiotic dosing, multiple hospital visits, or prolonged intravenous therapy at home. For adults, the entire treatment can be completed with a single 1,500 mg dose or two doses given one week apart.
Xydalba should be used with caution in patients with a known allergy to vancomycin or teicoplanin, as cross-sensitivity between glycopeptide antibiotics is possible. If you have had a previous allergic reaction to vancomycin, it is essential to inform your doctor before receiving Xydalba. Your doctor will carefully assess whether the potential benefits outweigh the risks in your specific situation. If you have had a severe or life-threatening reaction to a glycopeptide, alternative antibiotics should be considered.
Yes, Xydalba is effective against methicillin-resistant Staphylococcus aureus (MRSA). In fact, MRSA is one of the key pathogens that Xydalba is designed to treat. Dalbavancin has demonstrated potent bactericidal activity against MRSA in both laboratory testing and clinical trials. The DISCOVER clinical trials enrolled patients with MRSA infections and confirmed the clinical efficacy of dalbavancin in this important patient population.
Yes, Xydalba is approved for use in children from birth onwards for the treatment of acute bacterial skin and skin structure infections. The dose is calculated by the doctor based on the child’s age and body weight. Children aged 6 to under 18 years receive 18 mg/kg as a single dose, while infants and children from birth to under 6 years receive 22.5 mg/kg as a single dose. The maximum dose for any child is 1,500 mg. There is limited data on the use of Xydalba in children with kidney problems.
No, Xydalba must NOT be diluted with sodium chloride (normal saline) solutions. Saline solutions can cause dalbavancin to precipitate out of solution, rendering it unusable. Xydalba must be reconstituted with sterile water for injection and then diluted exclusively with 5% glucose (dextrose) solution. This is an important consideration for healthcare professionals preparing the infusion. If other medications are administered through the same IV line, the line should be flushed with 5% glucose solution before and after Xydalba.
References
- European Medicines Agency (EMA). Xydalba (dalbavancin) – Summary of Product Characteristics. Last updated 2025. Available at: www.ema.europa.eu
- U.S. Food and Drug Administration (FDA). Dalvance (dalbavancin) for injection – Prescribing Information. Revised 2024. Available at: www.fda.gov
- Boucher HW, Wilcox M, Talbot GH, et al. Once-weekly dalbavancin versus daily conventional therapy for skin infection. N Engl J Med. 2014;370(23):2169–2179. doi: 10.1056/NEJMoa1310480
- Dunne MW, Puttagunta S, Giordano P, et al. A randomized clinical trial of single-dose versus weekly dalbavancin for treatment of acute bacterial skin and skin structure infection. Clin Infect Dis. 2016;62(5):545–551. doi: 10.1093/cid/civ982
- Stevens DL, Bisno AL, Chambers HF, et al. Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the IDSA. Clin Infect Dis. 2014;59(2):e10–e52. doi: 10.1093/cid/ciu296
- Leuthner KD, Buechler KA, Kaye KS. Clinical efficacy of dalbavancin for the treatment of acute bacterial skin and skin structure infections (ABSSSI). Expert Opin Pharmacother. 2016;17(13):1765–1776.
- World Health Organization (WHO). WHO Model List of Essential Medicines – 23rd List. 2023. Available at: www.who.int
- European Society of Clinical Microbiology and Infectious Diseases (ESCMID). Guidelines for the treatment of skin and soft tissue infections. Clin Microbiol Infect. 2023.
Editorial Team
Medical Content
Written by the iMedic Medical Editorial Team – specialists in infectious diseases, clinical pharmacology, and antimicrobial therapy
Medical Review
Reviewed by the iMedic Medical Review Board according to WHO, EMA, FDA, and IDSA guidelines
Evidence Standard
GRADE evidence framework – Evidence Level 1A based on systematic reviews and randomized controlled trials
Editorial Independence
No commercial funding or pharmaceutical industry sponsorship. Fully independent medical content
Published: • Last reviewed: • Next review: